BAM
PTCT icon

Byrne Asset Management’s PTC Therapeutics PTCT Stock Holding History

Byrne Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25
Closed -$727 – 556
2024
Q1 		$727 Hold
25
– – ﹤0.01% 518
2023
Q4 		$734 Sell
25
-650
-96% -$14.9K ﹤0.01% 525
2023
Q3 		$15K Buy
+675
New +$25.1K 0.01% 301
2023
Q2 		– Sell
-675
Closed -$33K – 296
2023
Q1 		$33K Buy
675
+150
+29% +$6.86K 0.02% 259
2022
Q4 		$20K Hold
525
– – 0.01% 321
2022
Q3 		$26K Hold
525
– – 0.02% 264
2022
Q2 		$21K Hold
525
– – 0.02% 273
2022
Q1 		$20K Hold
525
– – 0.01% 309
2021
Q4 		$21K Buy
+525
New +$20.1K 0.01% 287

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Byrne Asset Management's PTCT Position: Q2 2024 in Review

Byrne Asset Management sold out of PTC Therapeutics (PTCT) in Q2 2024, closing a stake of 25 shares — an estimated $727 sold.

Byrne Asset Management first reported a position in PTCT in Q4 2021 and held it in 9 quarters. The position peaked at $33K in Q1 2023. 198 funds tracked by Wall St. Rank hold PTCT as of Q2 2024.

  • Byrne Asset Management reported no remaining PTC Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Byrne Asset Management sold 25 PTC Therapeutics shares in Q2 2024, an estimated $727.
  • Byrne Asset Management first reported a position in PTC Therapeutics in Q4 2021 and held it in 9 quarters.
  • Byrne Asset Management's PTC Therapeutics position peaked at $33K in Q1 2023.
  • 198 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2024.

Based on Byrne Asset Management's 13F filing for Q2 2024, filed 23 Jul 2024.